Celltrion Sees Double-Digit Growth In Sales And Profit
As Company’s Biosimilars Strategy Continues To Deliver
South Korea’s Celltrion saw a double-digit jump in sales and operating profit in 2020 based on continued growth for its leading biosimilars. Meanwhile, the company is pursuing its strategy of developing at least one biosimilar annually.
You may also be interested in...
Mid-table players jostle for position as we continue to work our way through Generics Bulletin’s annual Top 50, with mixed fortunes over the past year seeing some companies rise up the rankings as others decline.
Celltrion will adopt a “next generation” innovative approach to developing biosimilars as it continues to bolster its pipeline, HoUng Kim, head of Celltrion Healthcare’s medical and marketing division, tells Generics Bulletin in an exclusive interview. But the firm sees the US interchangeability designation as an “unnecessary” regulatory barrier.
South Korea’s Celltrion has announced positive results from its recent study on the real-world clinical effectiveness and safety of its Truxima (rituximab) or CT-P10 biosimilar in patients with diffuse large B-cell lymphoma. The company presented its findings at the recently held European Hematology Association 2021 virtual congress.